Foundry Partners LLC Grows Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Foundry Partners LLC increased its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 51.5% during the 4th quarter, Holdings Channel.com reports. The fund owned 5,092 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,730 shares during the quarter. Foundry Partners LLC’s holdings in Jazz Pharmaceuticals were worth $627,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of JAZZ. Pacer Advisors Inc. boosted its stake in shares of Jazz Pharmaceuticals by 5.5% during the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock valued at $272,713,000 after purchasing an additional 115,102 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Jazz Pharmaceuticals by 135.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after buying an additional 100,112 shares during the period. GW&K Investment Management LLC grew its holdings in Jazz Pharmaceuticals by 26.6% in the 4th quarter. GW&K Investment Management LLC now owns 464,003 shares of the specialty pharmaceutical company’s stock worth $57,142,000 after acquiring an additional 97,589 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Jazz Pharmaceuticals by 501.4% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 112,055 shares of the specialty pharmaceutical company’s stock valued at $13,800,000 after acquiring an additional 93,422 shares during the period. Finally, Raymond James Financial Inc. bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at about $11,373,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,800 shares of the business’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the completion of the transaction, the executive vice president now owns 33,318 shares of the company’s stock, valued at approximately $4,826,778.66. The trade was a 10.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO Robert Iannone sold 7,080 shares of the company’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the transaction, the chief marketing officer now owns 82,024 shares in the company, valued at $11,368,526.40. This represents a 7.95 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,736 shares of company stock worth $4,023,305. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $110.04 on Friday. The company has a market capitalization of $6.68 billion, a PE ratio of 15.50, a PEG ratio of 1.04 and a beta of 0.44. The business has a fifty day moving average price of $132.27 and a 200-day moving average price of $122.91. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $148.06. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Truist Financial boosted their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Piper Sandler restated an “overweight” rating and set a $176.00 target price (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and issued a $210.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 5th. Finally, UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price target for the company from $145.00 to $179.00 in a research report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $187.71.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.